Drug patent expiry dates aren’t just legal milestones—they’re commercial inflection points. And yet, most life sciences teams still treat them like back-office calendar events instead of revenue catalysts.
Here’s the agitation: when a patent cliff appr…

Sell the line—before the patent breaks.
In pharma manufacturing, timing isn’t just a competitive advantage. It’s the difference between being a “qualified supplier” and being the supplier that gets the first call when the market opens.
Drug patent cl…

The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/

Orphan drugs were built to help patients. But the incentives may be quietly reshaping the entire patent landscape.
For years, the pharmaceutical industry has lived with a familiar bargain: invest in R&D, earn time-limited exclusivity, and—ideally—d…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Biologics don’t just “run out.” They fall off a cliff—and the companies that win the next chapter are the ones that build the runway befor…

Generic competition is supposed to be the end of the story. For many branded drugmakers, it’s the beginning of a new one.
That’s the uncomfortable reality behind “evergreening”—the practice of using reformulations, new indications, and incremental pate…

Patients aren’t asking “about patents.” They’re asking: “Will this work for me?”
Drug switching is one of those topics that sounds clinical—until you watch what people actually type into search bars at 2 a.m.
A new DrugPatentWatch post, “Drug Switching…

Evergreening isn’t just a legal tactic—it’s a business strategy designed to delay competition, extend exclusivity, and protect revenue streams long after the original patent estate should have expired.
And if you’re still reacting to drug patent filing…

GPT, Rosalind, and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes
The life sciences industry loves a good “platform moment.” A new model drops. A new workflow appears. Everyone asks the same question: Will this replace scientists?
…

The patent cliff isn’t a surprise anymore. The real question is: who moves first?
In pharma, the “patent cliff” has become less of an event and more of a calendar. Everyone knows the date when exclusivity ends. Fewer companies are prepared for the oper…